Saturday 17 October 2026
Export VIVS’s income statement to Excel — free account
VivoSim Labs, Inc.
VIVS Healthcare Biotechnology
VivoSim Labs, Inc.’s revenue for fiscal 2026 (year ended March 2026) was $131,000.00, down 9.03% from fiscal 2025. In the quarter to June 2026, revenue fell 51.4%, EPS grew 78.1% and free cash flow grew 17.9%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.16
0.01
−5.88%
Follow VIVS
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
— | 5 | 3 | 4 |
| (36.91%) | (51.07%) | (294.75%) | (343.10%) | ||
| (24.12%) | (22.71%) | (125.64%) | (155.93%) | ||
ROIC |
(1,960.70%) | (4,678.92%) | 0.00% | 0.00% | |
Return on Tangible Assets |
(36.44%) | (32.17%) | (341.97%) | (810.64%) | |
Average Days of Receivables |
83.43 | 2,683.52 | 2,914.43 | 3,405.58 | |
Free Cash Flow per Share |
(3.90) | (4.07) | (4.18) | (0.22) | |
Free Cash Flow |
(10.15) | (10.62) | (10.83) | (1.14) | |
Capital Expenditures |
— | — | — | 8.96 | |
| Other line items | |||||
Cash ROIC |
(73.89%) | (121.71%) | (275.85%) | 168.05% | |
Accounts Receivable Turnover |
4.59 | 0.27 | 0.24 | 0.21 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
3,259.29% | 2,762.68% | 3,197.71% | 3,857.14% | |
Selling, General and Administrative Expense of Revenue |
5,533.57% | 5,403.52% | 5,670.99% | 6,359.82% | |
Share Based Compensation of Revenue |
265.00% | 216.90% | 231.30% | 282.14% | |
Interest Coverage |
— | (636.33) | (675.71) | (708.19) | |
Operating CF/Net income |
5.12 | 8.66 | 0.78 | 0.82 | |
Depreciation/Fixed assets |
0.83 | 0.94 | 1.04 | 1.03 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 46.21 | |
Revenue per Share |
0.05 | 0.05 | 0.05 | 0.02 | |
Operating CF per Share |
(3.90) | (4.07) | (4.18) | (1.93) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 1.71 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | (80.04) |
Columns are period end dates